At Tarian Pharma, we believe that supportive care deserves the same attention as primary cancer treatment. Tarian Gel is being developed to help prevent treatment-related skin toxicities before they affect patient comfort, adherence, and treatment continuity.
Our ambition is clear: to transform the skin toxicity management in oncology through a topical, science-based approach designed around prevention, protocol integration, and patient quality of life.
We aim for a future where every cancer treatment journey is supported from the surface to the core where healing doesn’t come at the cost of dignity, pain, or isolation.
Our ambition is to make holistic cancer care the standard, addressing both the disease and the physical and emotional impact of cancer treatment.
Cancer diagnosis and treatment can place a significant physical and emotional burden on patients. Tarian Gel is designed to integrate into oncology care pathways and daily life with the aim of supporting treatment continuity while limiting additional burden.
Support treatment continuity
Designed for oncology protocols
Once-daily home application
Dermatological side effects are among the most frequent and disruptive complications of cancer treatment. Rashes, burns, folliculitis, hairloss and painful skin reactions can lead to emotional distress, social withdrawal, and, in too many cases, treatment interruption.
We believe that skin protection should be proactive, not reactive.
Tarian Gel is the result of more than 200 formulation prototypes developed and refined by experts in dermatology and pharmaceutical science.
Tarian Gel is designed to be:
Its development aims to support treatment continuity, patient wellbeing, and the dignity of care.
Tarian Gel mimics the protective mechanism of cooling devices by inducing controlled, localized vasoconstriction in superficial cutaneous blood vessels.
This pharmacological approach is intended to reduce skin exposure to anticancer agents without the pain and logistical limitations associated with physical cooling.
By modulating cutaneous microcirculation, Tarian Gel reduces local skin exposure to chemotherapeutic agents and help prevent treatment-related dermatologic adverse events.
TAR-0520 is an investigational medicinal product. It has not been approved for commercial use. The information provided on this website is intended for general informational purposes only and does not constitute medical advice or promotional communication.
To provide the best experiences, we use technologies such as cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent or withdrawing consent may adversely affect certain features and functions.